Study of Abobotulinum Toxin Versus Neubotulinum Toxin Injection For Hemifacial Spasm in Thai Patients
Status:
Not yet recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
A 48-Week Prospective, Double-Blinded, Randomized, Cross-over design in Multicenter Study of,
100 unit of Abobotulinum Toxin Type A (Dysport) and 33.33 unit of Neubotulinum Toxin Type A
(Neuronox) injection for Hemifacial Spasm in patient diagnosed with Hemifacial Spasm
according to clinical diagnosis. It was designed to evaluate the efficacy, safety,
tolerability, quality of life and the comparesion the improvement after treatment by of
Abobotulinum Toxin Type A (Dysport) injection versus Neubotulinum Toxin Type A (Neuronox)
Injection.
Phase:
Phase 3
Details
Lead Sponsor:
Rajavithi Hospital
Treatments:
abobotulinumtoxinA Botulinum Toxins Botulinum Toxins, Type A